Glioblastoma heterogeneity
Glioblastoma recurs because cells at the margin escape surgery, yet the tumour core is often used to benchmark treatments. Combining fluorescence-guided sampling, a microfluidic adhesion assay and live-cell imaging on patient-derived cells, we showed that cells differ in adhesion and migration, and therefore in invasive potential (Rezk et al., Neuro-Oncology Advances 2020). Mechanobiological heterogeneity has to be measured and taken into account when treatments are validated. A 2025 follow-up shows that it also affects the response to metabolic and adhesion inhibitors (Rezk et al., Clinical and Experimental Medicine 2025). The project was led by Rasha Rezk when she was a post-doctoral research associate in Cambridge, and funded by the Nabaa El Mahaba charity (2018 to 2020).